International Investment Strategies and Location Benchmarking Study This NEW PUBLICATION OFFER provides buyers (*) of the report with the opportunity of having their own city, regional or national location BENCHMARKED against 49 key global MedTech clusters including California; Chile; London; Massachusetts; Ontario; Paris; The Netherlands; Ireland; Costa Rica; Singapore and India. The MedTech Report 2008 looks at the international direction and foreign direct investment strategies of biotechnology, pharmaceutical and medical technology companies and the role of economic development agencies in assisting them. It also provides an independent benchmarking analysis of key locations in Western Europe, Eastern Europe, North America and Asia-Pacific, presenting their attractiveness and strengths as a location for international MedTech companies. Oxford Intelligence has previously published two major reports on inward investment strategies and location benchmarking in the life sciences, biotechnology and medical device sectors - in 2002 and 2006. Since that time, there have been many changes in the global economic and political situation. Report Benefits The report is a strategic but practical tool that provides information on: - Key industry and market growth trends and forecasts
- New trends and emerging opportunities for foreign direct investment potential
- How the key location drivers have changed since 2005
- Which location attributes have become more important for companies
- How key Global MedTech regions compare against each other in terms of attractiveness
- How corporate perceptions and usage of inward investment agencies have changed since 2002
- How development agencies can deliver services of genuine value to companies
Report Structure Part 1 – Industry Trends and International Investment Strategies Part 1 is divided into two core sections. The first section provides an overview of global and European market trends statistics, a review of key growth segments, foreign direct investment statistics, mergers and acquisitions and venture capital funding. The second section focuses on key industry issues and challenges; an analysis of future international corporate investment strategies; an analysis of the key drivers in investment location selection; and an appraisal of the role of economic development agencies and professional services providers in assisting MedTech companies in their international investment projects.
Part 2 – Corporate Location Benchmarking Analysis
Part 2 is divided into two core sections: Executive Perceptions and Location BenchmarkingThe Executive Perceptions section presents the findings of the Oxford Intelligence company survey regarding corporate executives’ perceptions of the best locations for life sciences and medical technology research. This section also explores executives’ perceptions regarding key emerging locations for MedTech companies around the world. The Location Benchmarking section provides simplified corporate location benchmarking analysis for 27 European locations, 15 Americas locations and seven Asia-Pacific locations. The analysis presented in this report concentrates on a top-level comparison and the aim is to provide indicative rankings of location attractiveness for manufacturing and for research and development facilities. For each global region - Americas, Asia-Pacific and Europe, the following benchmarking models are provided: Location Quality Rankings - Overall composite ranking of attractiveness to MedTech companies
- Ranking for a manufacturing facility for medical technology products
- Ranking for a research and development facility for medical technology products
- Ranking for a manufacturing facility for pharmaceuticals and biotechnology
- Ranking for a biotechnology/pharmaceutical research and development facility
Location Cost Rankings - Annual operating costs for a 100 person manufacturing facility
- Annual operating costs for a 50 person R&D facility
Cost Quality Positioning - Medical technology manufacturing facility
- Medical technology research and development facility
- Biotechnology/pharmaceutical manufacturing facility
- Biotechnology/pharmaceutical research and development facility
The full report is now available in both printed and electronic formats.
(*) offer valid for buyers of the full report or of Part 2: Location Benchmarking Analysis – if the region is not currently included in the Location Benchmarking. Buyers will be expected to provide local data for the benchmarking exercise |
